02052nam a2200409 i 4500001001300000003000600013005001700019006001900036007001500055008004100070040003700111042000800148043001200156050002200168074002300190086002300213088009000236099002300326110010700349245026200456264006000718300003800778336002600816337002600842338003600868588012000904500010801024504004101132500002601173500002501199650005101224650006801275655003301343776020801376856003901584999001901623ocn968792727OCoLC20170210123720.0m     o  d f      cr bn||||a||||170117s2016    dcua    ob   f000 0 eng c  aGPObengerdaepncGPOdGPOdMvI  apcc  an-us---14aKF27b.E553 2016a  a1019-C-01 (online)0 aY 4.C 73/8:114-114  aSerial no. 114-114 (United States. Congress. House. Committee on Energy and Commerce)  aY 4.C 73/8:114-1141 aUnited States.bCongress.bHouse.bCommittee on Energy and Commerce.bSubcommittee on Health,eauthor.10aExamining implementation of the Biologics Price Competition and Innovation Act :bhearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Fourteenth Congress, second session, February 4, 2016. 1aWashington :bU.S. Government Publishing Office,c2016.  a1 online resource (iii, 83 pages)  atextbtxt2rdacontent  acomputerbc2rdamedia  aonline resourcebcr2rdacarrier  aDescription based on online resource, PDF version; title from title page (FDsys web site, viewed on Jan. 17, 2017).  aPaper version available for sale by the Superintendent of Documents, U.S. Government Publishing Office.  aIncludes bibliographical references.  a"Serial No. 114-114."  aCRDP Program record. 0aBiologicalsxGovernment policyzUnited States. 0aPharmaceutical biotechnologyxGovernment policyzUnited States. 7aLegislative hearings.2lcgft08iPrint version:aUnited States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health.tExamining implementation of the Biologics Price Competition and Innovation Actw(OCoLC)97102793540uhttps://purl.fdlp.gov/GPO/gpo76617  c257407d257407